Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>IQVIA's recent earnings report for the third quarter of 2025 presents a nuanced picture of the company's performance and future prospects.</li><li>On the positive side, IQVIA achieved revenue growth towards the high end of its guidance, driven by strong operational execution and a beneficial industry environment.</li><li>The company's free cash flow for the quarter was notably high, marking the best quarterly performance even when compared to the pandemic-era advances for vaccine trials.</li></ul>

IQVIA's recent earnings report for the third quarter of 2025 presents a nuanced picture of the company's performance and future prospects.On the positive side, IQVIA achieved revenue growth towards the high end of its guidance, driven by strong operational execution and a beneficial industry environment.The company's free cash flow for the quarter was notably high, marking the best quarterly performance even when compared to the pandemic-era advances for vaccine trials.

IQVIA’s AI Ambition Exposed: Inside the Race to Deploy 500 Smart Agents by 2027!

<ul><li>IQVIA marked a significant milestone in the second quarter of 2025 by surpassing $4 billion in quarterly revenue, a first in the company's history.</li><li>This revenue achievement was noted to be above the high end of the anticipated guidance.</li><li>Adjusted EBITDA and adjusted diluted EPS also performed well, aligning with or eclipsing the expected targets.</li></ul>

IQVIA marked a significant milestone in the second quarter of 2025 by surpassing $4 billion in quarterly revenue, a first in the company's history.This revenue achievement was noted to be above the high end of the anticipated guidance.Adjusted EBITDA and adjusted diluted EPS also performed well, aligning with or eclipsing the expected targets.

IQVIA Holdings Inc.: AI & Technology Implementation to Position IQVIA At The Forefront Of Innovation In Life Sciences & Healthcare!

<ul><li>IQVIA's recent financial performance and strategic direction provide a nuanced picture of its current position within the life sciences sector.</li><li>In the first quarter of 2025, IQVIA reported strong financial results, achieving revenue growth at the high end of its expectations despite facing a challenging environment in Research & Development Solutions (R&DS).</li><li>The company recorded total revenue of $3.829 billion, marking a 2.5% increase on a reported basis and a 3.5% rise at constant currency.</li></ul>

IQVIA's recent financial performance and strategic direction provide a nuanced picture of its current position within the life sciences sector.In the first quarter of 2025, IQVIA reported strong financial results, achieving revenue growth at the high end of its expectations despite facing a challenging environment in Research & Development Solutions (R&DS).The company recorded total revenue of $3.829 billion, marking a 2.5% increase on a reported basis and a 3.5% rise at constant currency.

IQVIA Holdings Looking To Unlock Healthcare Innovation with High-Margin

<ul><li>IQVIA Holdings Inc. has reported its fourth-quarter and full-year 2024 earnings, showcasing a mixed but overall resilient financial performance in a challenging landscape.</li><li>Despite facing hindrances such as the Inflation Reduction Act impacts, geopolitical unrest, high interest rates, and inflation, the company has displayed significant achievements and noticeable resilience.</li><li>On the positive side, IQVIA has recorded a full-year revenue growth of 5.5% at constant currency excluding COVID-related declines, with adjusted diluted earnings per share rising by over 9%.</li></ul>

IQVIA Holdings Inc. has reported its fourth-quarter and full-year 2024 earnings, showcasing a mixed but overall resilient financial performance in a challenging landscape.Despite facing hindrances such as the Inflation Reduction Act impacts, geopolitical unrest, high interest rates, and inflation, the company has displayed significant achievements and noticeable resilience.On the positive side, IQVIA has recorded a full-year revenue growth of 5.5% at constant currency excluding COVID-related declines, with adjusted diluted earnings per share rising by over 9%.

IQVIA Holdings: Mergers & Acquisitions Strategy Is a Significant Needle Mover!

External broker reports(aggregated public sources), CMB International

CMB International

External broker reports(aggregated public sources)

Incorporated in Hong Kong, supported by the mainland and targeting in global market, CMB International Capital Corporation Limited (“CMBI”) is an integrated financial institution providing comprehensive and professional services. As a wholly-owned subsidiary of China Merchants Bank ("CMB"), by leveraging on the Group’s synergy and coordination in domestic and overseas markets, as well as CMB’s strong resources and outstanding social reputation, CMBI and its subsidiaries have been actively implementing diversified business strategies and set up an overall layout of main business segments including Corporate Finance, Asset Management, Wealth Management, Global Markets and Structured Finance, etc. Adhering to the philosophy of “being clients oriented and increasing our own values by the way of creating value for clients”, CMBI endeavors to provide quality and integrated financial services to institutional, corporate and individual customers both domestic and overseas including Hong Kong IPO sponsorship and underwriting, share placement and rights issue for listed companies, financial advisors, bonds issuance services, asset management, direct investment, wealth management, equity sales and trading, etc.

Thematic (Sector/Industry)

<ul><li>We have analyzed the 2024 and 4Q24 financial results of key overseas CXOs and upstream companies, covering clinical CROs, preclinical CROs, C(D)MOs, and life science tools suppliers.</li><li>While the companies in our coverage universe continued to face pressure on revenue and profit growth in 2024, half demonstrated improved performance in 2H24 versus 1H24.</li><li>Specifically, C(D)MOs and life science tools suppliers showed positive trends in financial performance, demand outlook, and guidance for 2025. </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

We have analyzed the 2024 and 4Q24 financial results of key overseas CXOs and upstream companies, covering clinical CROs, preclinical CROs, C(D)MOs, and life science tools suppliers.While the companies in our coverage universe continued to face pressure on revenue and profit growth in 2024, half demonstrated improved performance in 2H24 versus 1H24.Specifically, C(D)MOs and life science tools suppliers showed positive trends in financial performance, demand outlook, and guidance for 2025. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Healthcare - Results Review of Overseas CXO and Life Science Tools Sectors in 2024 & 4Q24

United States

IQVIA Holdings Inc. focuses on technology solutions and contract research services. The Company offers a broad range of solutions which includes clinical development strategies, therapeutic expertise, predictive and prescriptive analytics, and patient retention services. IQVIA Holdings serves consumer health, biopharma, and medical technology industries globally.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Iqvia Holdings (IQV US)

IQVIA’s AI Ambition Exposed: Inside the Race to Deploy 500 Smart Agents by 2027!

IQVIA's recent earnings report for the third quarter of 2025 presents a nuanced picture of the company's performance and future prospects. On the...

Baptista Research

IQVIA Holdings Inc.: AI & Technology Implementation to Position IQVIA At The Forefront Of Innovation In Life Sciences & Healthcare!

IQVIA marked a significant milestone in the second quarter of 2025 by surpassing $4 billion in quarterly revenue, a first in the company's...

Baptista Research

IQVIA Holdings Looking To Unlock Healthcare Innovation with High-Margin

IQVIA's recent financial performance and strategic direction provide a nuanced picture of its current position within the life sciences sector. In...

Baptista Research

IQVIA Holdings: Mergers & Acquisitions Strategy Is a Significant Needle Mover!

IQVIA Holdings Inc. has reported its fourth-quarter and full-year 2024 earnings, showcasing a mixed but overall resilient financial performance in...

Baptista Research

Healthcare - Results Review of Overseas CXO and Life Science Tools Sectors in 2024 & 4Q24

We have analyzed the 2024 and 4Q24 financial results of key overseas CXOs and upstream companies, covering clinical CROs, preclinical CROs,...

CMB International

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)